HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

Q2 2021 13F Holders as of 30 Jun 2021

Type / Class
Equity / Common Stock
Shares outstanding
123,650,000
Number of holders
309
Total 13F shares, excl. options
129,727,357
Shares change
-2,036,817
Total reported value, excl. options
$5,890,257,760
Value change
-$85,620,767
Put/Call ratio
96.42%
Number of buys
147
Number of sells
-150
Price
$45.41

Significant Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q2 2021

370 filings reported holding HALO - HALOZYME THERAPEUTICS, INC. - Common Stock as of Q2 2021.
HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) has 309 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 129,727,357 shares .
Largest 10 shareholders include BlackRock Inc. (19,066,438 shares), VANGUARD GROUP INC (13,638,304 shares), Artisan Partners Limited Partnership (10,189,688 shares), Invesco Ltd. (5,651,622 shares), JPMORGAN CHASE & CO (5,255,208 shares), STATE STREET CORP (5,161,793 shares), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (4,882,486 shares), SNYDER CAPITAL MANAGEMENT L P (3,176,404 shares), MACQUARIE GROUP LTD (2,941,938 shares), and GEODE CAPITAL MANAGEMENT, LLC (2,446,622 shares).
This table shows the top 309 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
Investor Option Weight % Change % Value $ * Price $ Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.